A Study of PF-04217903 in Patients With Advanced Cancer

Stopped early · Phase 1

Conditions studied: Neoplasms

In brief

PF-04217903 may work in cancer by blocking the cell growth, migration and invasion of tumor cells. PF-04217903 is a new member in a class of drugs called c-Met/hepatocyte growth factor receptor tyrosine kinase inhibitors. This research study is the first time PF-04217903 will be given to patients. PF-04217903 is taken by mouth daily.

Key facts

Study ID

NCT00706355

Run by

Pfizer

People needed

16

Starts

2008-08-01

Expected to finish

2011-06-01

Last updated by the study team

2012-06-25

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Advanced solid tumors, histologically proven at diagnosis which is refractory to standard of care or for whom no standard of care therapy is available
• Adequate blood cell counts, normal kidney function, and performance status of 0 or 1

You may not qualify if…

• Major surgery, radiation therapy or anti-cancer therapy within 2 weeks of starting study treatment
• Prior stem cell transplant
• Active or unstable cardiac disease or heart attack within 12 months of starting study treatment

Where it is running

• Pfizer Investigational Site — Aurora, Colorado, United States
• Pfizer Investigational Site — Chicago, Illinois, United States
• Pfizer Investigational Site — Boston, Massachusetts, United States
• Pfizer Investigational Site — Boston, Massachusetts, United States
• Pfizer Investigational Site — Boston, Massachusetts, United States
• Pfizer Investigational Site — Detroit, Michigan, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.